{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:46:35Z","timestamp":1790837195262,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s10456-018-9623-8","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:29:29Z","timestamp":1526862569000},"page":"793-804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models"],"prefix":"10.1007","volume":"21","author":[{"given":"Elaine","family":"Reguera-Nu\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Kerbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"9623_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jason","year":"2016","unstructured":"Jason GC, Kerbel R, Ellis LM, Harris AL (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet 388:518\u2013529","journal-title":"Lancet"},{"key":"9623_CR2","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","volume":"30","author":"R Motzer","year":"2012","unstructured":"Motzer R, Hutson TE, Olsen MR et al (2012) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30:1371\u20131377","journal-title":"J Clin Oncol"},{"key":"9623_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: an international, multicentre, prospective, randomised, placebo controlled phase 3 trial (GRID). Lancet 381:295\u2013302","journal-title":"Lancet"},{"key":"9623_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312","journal-title":"Lancet"},{"key":"9623_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomized controlled trial. Lancet Oncol 15:143\u2013155","journal-title":"Lancet Oncol"},{"key":"9623_CR6","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","volume":"14","author":"BI Rini","year":"2013","unstructured":"Rini BI, Melichar B, Ueda T et al (2013) Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 14:1233\u20131242","journal-title":"Lancet Oncol"},{"key":"9623_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.urolonc.2013.10.004","volume":"32","author":"GA Bjarnason","year":"2014","unstructured":"Bjarnason GA, Khalil B, Hudson JM et al (2014) Outcomes in patients with metastatic renal cell carcinoma treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol 32:480\u2013487","journal-title":"Urol Oncol"},{"key":"9623_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12885-018-4209-9","volume":"18","author":"A Mar\u00e1z","year":"2018","unstructured":"Mar\u00e1z A, Cserh\u00e1ti A, Uhercs\u00e1k G et al (2018) Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. BioMed Cent Cancer 18:296. \n                    https:\/\/doi.org\/10.1186\/s12885-018-4209-9","journal-title":"BioMed Cent Cancer"},{"key":"9623_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1593\/neo.101334","volume":"13","author":"B Canu","year":"2011","unstructured":"Canu B, Fioravanti A, Orlandi P et al. (2011) Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and in vivo and improves its anticancer activity in vivo. Neoplasia 13:217\u2013229","journal-title":"Neoplasia"},{"key":"9623_CR10","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","volume":"17","author":"KJ Gotink","year":"2011","unstructured":"Gotink KJ, Broxterman HJ, Labots M et al (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17:7337\u20137346","journal-title":"Clin Cancer Res"},{"key":"9623_CR11","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/bjc.2013.420","volume":"109","author":"M Santoni","year":"2013","unstructured":"Santoni M, Amantini C, Morelli MB et al (2013) Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumor cells. Br J Cancer 109:1040\u20131050","journal-title":"Br J Cancer"},{"key":"9623_CR12","doi-asserted-by":"publisher","first-page":"42396","DOI":"10.18632\/oncotarget.6377","volume":"6","author":"T Desidero Di","year":"2015","unstructured":"Di Desidero T, Xu P, Man S, Bocci G, Kerbel RS (2015) Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget 6:42396\u201342410","journal-title":"Oncotarget"},{"key":"9623_CR13","doi-asserted-by":"publisher","first-page":"282ra50","DOI":"10.1126\/scitranslmed.3010722","volume":"7","author":"C Jedeszko","year":"2015","unstructured":"Jedeszko C, Paez-Ribes M, Di Desidero T et al. (2015) Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent anti-tumor activity of metronomic oral topotecan with pazopanib. Sci Transl Med 7:282ra50 \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3010722","journal-title":"Sci Transl Med"},{"key":"9623_CR14","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","volume":"6","author":"R Kumar","year":"2007","unstructured":"Kumar R, Knick VB, Rudolph SK et al (2007) Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6:2012\u20132021","journal-title":"Mol Cancer Ther"},{"key":"9623_CR15","doi-asserted-by":"publisher","first-page":"844","DOI":"10.18632\/oncoscience.106","volume":"1","author":"KJ Gotink","year":"2014","unstructured":"Gotink KJ, Broxterman HJ, Honeywell RJ et al (2014) Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience 1:844\u2013852","journal-title":"Oncoscience"},{"key":"9623_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-016-0411-2","volume":"35","author":"M Rovithi","year":"2016","unstructured":"Rovithi M, de Haas RR, Honeywell RJ et al (2016) Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth. J Exp Clin Cancer Res 35:138. \n                    https:\/\/doi.org\/10.1186\/s13046-016-0411-2","journal-title":"J Exp Clin Cancer Res"},{"key":"9623_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1479-5876-9-220","volume":"9","author":"X Wang","year":"2011","unstructured":"Wang X, Zhang L, Goldberg SN et al (2011) High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med 9:220. \n                    https:\/\/doi.org\/10.1186\/1479-5876-9-220","journal-title":"J Transl Med"},{"key":"9623_CR18","first-page":"31","volume":"1845","author":"M Buczek","year":"2014","unstructured":"Buczek M, Escudier B, Bartnik E, Szczylik C, Czarnecka A (2014) Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from patient\u2019s bed to molecular mechanisms. Biochem Biophys Acta 1845:31\u201341","journal-title":"Biochem Biophys Acta"},{"key":"9623_CR19","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","volume":"10","author":"B Rini","year":"2009","unstructured":"Rini B, Atkins M (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10:992\u20131000","journal-title":"Lancet Oncol"},{"key":"9623_CR20","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280\u20131289","journal-title":"J Clin Oncol"},{"key":"9623_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1593\/neo.10804","volume":"12","author":"T Tang","year":"2010","unstructured":"Tang T, Man S, Xu P et al (2010) Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 12:928\u2013940","journal-title":"Neoplasia"},{"key":"9623_CR22","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1002\/cncr.25583","volume":"116","author":"I Zama","year":"2010","unstructured":"Zama I, Hutson TE, Elson P et al (2010) Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116:5400\u20135406","journal-title":"Cancer"},{"key":"9623_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1464-410X.2011.10421.x","volume":"109","author":"A Mancuso","year":"2011","unstructured":"Mancuso A, Di Paola ED, Leone A et al (2011) Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. Br J Urol Int 109:200\u2013206","journal-title":"Br J Urol Int"},{"key":"9623_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.clgc.2012.03.001","volume":"10","author":"R Amato","year":"2012","unstructured":"Amato R, Zhai J, Willis J, Saxena S, DeFoe M (2012) A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 10:153\u2013158","journal-title":"Clin Genitourin Cancer"},{"key":"9623_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/0008-5472.CAN-14-3687","volume":"75","author":"E Kuczynski","year":"2015","unstructured":"Kuczynski E, Lee CR, Man S, Chen E, Kerbel RS (2015) Effects of sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma. Can Res 75:1\u201310","journal-title":"Can Res"},{"key":"9623_CR26","doi-asserted-by":"publisher","first-page":"e275-280","DOI":"10.1016\/j.clgc.2016.08.014","volume":"15","author":"MC Ornstein","year":"2017","unstructured":"Ornstein MC, Wood L, Elson P et al (2017) Clinical effect of dose escalation after disease progression in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 15:e275-280","journal-title":"Clin Genitourin Cancer"},{"key":"9623_CR27","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"B Rini","year":"2011","unstructured":"Rini B, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931\u20131939","journal-title":"Lancet"},{"key":"9623_CR28","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1007\/s12032-011-0073-z","volume":"29","author":"C Porta","year":"2012","unstructured":"Porta C, Powles T (2012) Sequential therapy in metastatic renal cell carcinoma: what comes next? Med Oncol 29:1914\u20131915","journal-title":"Med Oncol"},{"key":"9623_CR29","first-page":"3301","volume":"66","author":"R Munoz","year":"2006","unstructured":"Munoz R, Man S, Shaked Y et al (2006) Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Can Res 66:3301\u20133386","journal-title":"Can Res"},{"key":"9623_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10549-010-0788-0","volume":"121","author":"CH Barrios","year":"2010","unstructured":"Barrios CH, Liu MC, Lee SC et al (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121\u2013131","journal-title":"Breast Cancer Res Treat"},{"key":"9623_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.clbc.2011.03.005","volume":"11","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Saleh MN, Paul D et al (2011) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 11:82\u201392","journal-title":"Clin Breast Cancer"},{"key":"9623_CR32","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","volume":"30","author":"J Bergh","year":"2012","unstructured":"Bergh J, Bondarenko IM, Lichinitser MR et al (2012) First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 30:921\u2013929","journal-title":"J Clin Oncol"},{"key":"9623_CR33","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1200\/JCO.2012.43.3391","volume":"31","author":"JP Crown","year":"2013","unstructured":"Crown JP, Di\u00e9ras V, Staroslawska E et al (2013) Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 31:2870\u20132878","journal-title":"J Clin Oncol"},{"key":"9623_CR34","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1158\/0008-5472.CAN-12-4183","volume":"73","author":"E Guerin","year":"2013","unstructured":"Guerin E, Man S, Xu P, Kerbel RS (2013) A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Can Res 73:2743\u20132748","journal-title":"Can Res"},{"key":"9623_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/path.4845","volume":"241","author":"VL Bridgeman","year":"2017","unstructured":"Bridgeman VL, Vermeulen PB, Foo S et al (2017) Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis. J Pathol 241:362\u2013374","journal-title":"J Pathol"},{"key":"9623_CR36","first-page":"4109","volume":"46","author":"S Naito","year":"1986","unstructured":"Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ (1986) Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Can Res 46:4109\u20134115","journal-title":"Can Res"},{"key":"9623_CR37","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1158\/1535-7163.MCT-09-0960","volume":"9","author":"K Hashimoto","year":"2010","unstructured":"Hashimoto K, Man S, Xu P et al (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9:996\u20131006","journal-title":"Mol Cancer Ther"},{"key":"9623_CR38","doi-asserted-by":"publisher","first-page":"85ra47","DOI":"10.1126\/scitranslmed.3002004","volume":"3","author":"N Suwaki","year":"2011","unstructured":"Suwaki N, Vanhecke E, Atkins KM et al (2011) A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med 3:85ra47. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3002004","journal-title":"Sci Transl Med"},{"key":"9623_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JML Ebos","year":"2009","unstructured":"Ebos JML, Lee CR, Cruz-Munoz W et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232\u2013239","journal-title":"Cancer Cell"},{"key":"9623_CR40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/path.4052","volume":"227","author":"A Chung","year":"2012","unstructured":"Chung A, Kowanetz M, Wu X et al (2012) Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol 227:404\u2013416","journal-title":"J Pathol"},{"issue":"11-12Supl7","key":"9623_CR41","doi-asserted-by":"publisher","first-page":"S252","DOI":"10.5489\/cuaj.4293","volume":"10","author":"GA Bjarnason","year":"2016","unstructured":"Bjarnason GA (2016) Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients? Can Urol Assoc J 10(11-12Supl7):S252\u2013S255","journal-title":"Can Urol Assoc J"},{"key":"9623_CR42","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1126\/science.355.6330.1144","volume":"355","author":"J Kaiser","year":"2017","unstructured":"Kaiser J (2017) When less is more. Science 355:1144\u20131146","journal-title":"Science"},{"key":"9623_CR43","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1200\/JCO.2016.71.1184","volume":"35","author":"MC Ornstein","year":"2017","unstructured":"Ornstein MC, Wood LS, Elson P et al (2017) A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma. J Clin Oncol 35:1764\u20131769","journal-title":"J Clin Oncol"},{"key":"9623_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10456-017-9555-8","volume":"20","author":"M Rovithi","year":"2017","unstructured":"Rovithi M, Verheul HMW (2017) Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity. Angiogenesis 20:287\u2013289","journal-title":"Angiogenesis"},{"key":"9623_CR45","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.humpath.2005.01.011","volume":"36","author":"L Huo","year":"2005","unstructured":"Huo L, Sugimura J, Tretiakova MS et al (2005) C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol 36:262\u2013268","journal-title":"Hum Pathol"},{"key":"9623_CR46","first-page":"251","volume":"34","author":"RE Brown","year":"2004","unstructured":"Brown RE, Lun M, Prichard JW, Blasick TM, Zhang PL (2004) Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines. Ann Clin Lab Sci 34:251\u2013262","journal-title":"Ann Clin Lab Sci"},{"key":"9623_CR47","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nbt.2017","volume":"29","author":"T Anastassiadis","year":"2011","unstructured":"Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 29:1039\u20131045","journal-title":"Nat Biotechnol"},{"key":"9623_CR48","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cellsig.2012.02.011","volume":"24","author":"MP S\u00e1nchez-Bail\u00f3n","year":"2012","unstructured":"S\u00e1nchez-Bail\u00f3n MP, Calcabrini A, G\u00f3mez-Dom\u00ednguez D et al (2012) Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells. Cell Signal 24:1276\u20131286","journal-title":"Cell Signal"},{"key":"9623_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220\u2013231","journal-title":"Cancer Cell"},{"key":"9623_CR50","doi-asserted-by":"publisher","first-page":"5488","DOI":"10.1158\/1078-0432.CCR-15-0915","volume":"21","author":"M Paez-Ribes","year":"2015","unstructured":"Paez-Ribes M, Man S, Xu P, Kerbel RS (2015) Potential proinvasive or metastatic effects of preclinical antiangiogenic therapy are prevented by concurrent chemotherapy. Clin Cancer Res 21:5488\u20135498","journal-title":"Clin Cancer Res"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10456-018-9623-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-018-9623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-018-9623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T14:46:39Z","timestamp":1558449999000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10456-018-9623-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["9623"],"URL":"https:\/\/doi.org\/10.1007\/s10456-018-9623-8","relation":{},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"value":"0969-6970","type":"print"},{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,21]]},"assertion":[{"value":"5 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}